Intrinsic value of Natus Medical - BABY

Previous Close

$28.15

  Intrinsic Value

$114.04

stock screener

  Rating & Target

str. buy

+305%

Previous close

$28.15

 
Intrinsic value

$114.04

 
Up/down potential

+305%

 
Rating

str. buy

*Intrinsic value change (in %) minus stock price change (in %) in the past 12 months.

We calculate the intrinsic value of BABY stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Shares outstanding, mln

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
2016(a)
   2017
   2018
   2019
   2020
   2021
   2022
   2023
   2024
   2025
   2026
   2027
   2028
   2029
   2030
   2031
   2032
   2033
   2034
   2035
   2036
   2037
   2038
   2039
   2040
   2041
   2042
   2043
   2044
   2045
   2046

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  1.60
  35.20
  32.18
  29.46
  27.02
  24.81
  22.83
  21.05
  19.44
  18.00
  16.70
  15.53
  14.48
  13.53
  12.68
  11.91
  11.22
  10.60
  10.04
  9.53
  9.08
  8.67
  8.30
  7.97
  7.68
  7.41
  7.17
  6.95
  6.76
  6.58
  6.42
Revenue, $m
  382
  516
  683
  884
  1,123
  1,401
  1,721
  2,083
  2,488
  2,936
  3,427
  3,959
  4,532
  5,145
  5,797
  6,488
  7,215
  7,980
  8,781
  9,618
  10,491
  11,401
  12,348
  13,332
  14,356
  15,419
  16,525
  17,673
  18,867
  20,109
  21,401
Variable operating expenses, $m
 
  426
  559
  720
  912
  1,136
  1,392
  1,683
  2,008
  2,367
  2,761
  3,177
  3,636
  4,128
  4,652
  5,206
  5,790
  6,403
  7,046
  7,718
  8,418
  9,148
  9,908
  10,698
  11,519
  12,373
  13,260
  14,181
  15,140
  16,136
  17,172
Fixed operating expenses, $m
 
  9
  9
  10
  10
  10
  10
  11
  11
  11
  12
  12
  12
  12
  13
  13
  13
  14
  14
  14
  15
  15
  15
  16
  16
  17
  17
  18
  18
  18
  19
Total operating expenses, $m
  327
  435
  568
  730
  922
  1,146
  1,402
  1,694
  2,019
  2,378
  2,773
  3,189
  3,648
  4,140
  4,665
  5,219
  5,803
  6,417
  7,060
  7,732
  8,433
  9,163
  9,923
  10,714
  11,535
  12,390
  13,277
  14,199
  15,158
  16,154
  17,191
Operating income, $m
  55
  82
  114
  154
  201
  255
  318
  390
  469
  558
  654
  770
  883
  1,004
  1,133
  1,269
  1,412
  1,563
  1,721
  1,886
  2,058
  2,238
  2,424
  2,618
  2,820
  3,030
  3,248
  3,474
  3,710
  3,955
  4,209
EBITDA, $m
  72
  104
  140
  183
  235
  296
  366
  445
  533
  631
  737
  853
  978
  1,112
  1,254
  1,405
  1,564
  1,730
  1,905
  2,088
  2,278
  2,477
  2,683
  2,898
  3,121
  3,353
  3,594
  3,845
  4,106
  4,377
  4,658
Interest expense (income), $m
  0
  5
  8
  11
  16
  21
  27
  33
  41
  50
  59
  70
  81
  93
  106
  120
  135
  150
  166
  184
  201
  220
  239
  259
  280
  302
  325
  348
  373
  398
  424
Earnings before tax, $m
  55
  77
  106
  142
  185
  235
  292
  356
  428
  508
  595
  701
  802
  911
  1,027
  1,149
  1,278
  1,413
  1,554
  1,702
  1,857
  2,018
  2,185
  2,359
  2,540
  2,728
  2,923
  3,126
  3,337
  3,557
  3,785
Tax expense, $m
  12
  21
  29
  38
  50
  63
  79
  96
  116
  137
  161
  189
  217
  246
  277
  310
  345
  381
  420
  460
  501
  545
  590
  637
  686
  737
  789
  844
  901
  960
  1,022
Net income, $m
  43
  56
  78
  104
  135
  171
  213
  260
  313
  371
  434
  512
  586
  665
  749
  839
  933
  1,031
  1,135
  1,243
  1,355
  1,473
  1,595
  1,722
  1,854
  1,991
  2,134
  2,282
  2,436
  2,596
  2,763

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  248
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  649
  542
  716
  927
  1,178
  1,470
  1,806
  2,186
  2,611
  3,081
  3,596
  4,154
  4,755
  5,399
  6,083
  6,808
  7,571
  8,374
  9,214
  10,092
  11,009
  11,963
  12,957
  13,990
  15,064
  16,180
  17,340
  18,545
  19,798
  21,101
  22,456
Adjusted assets (=assets-cash), $m
  401
  542
  716
  927
  1,178
  1,470
  1,806
  2,186
  2,611
  3,081
  3,596
  4,154
  4,755
  5,399
  6,083
  6,808
  7,571
  8,374
  9,214
  10,092
  11,009
  11,963
  12,957
  13,990
  15,064
  16,180
  17,340
  18,545
  19,798
  21,101
  22,456
Revenue / Adjusted assets
  0.953
  0.952
  0.954
  0.954
  0.953
  0.953
  0.953
  0.953
  0.953
  0.953
  0.953
  0.953
  0.953
  0.953
  0.953
  0.953
  0.953
  0.953
  0.953
  0.953
  0.953
  0.953
  0.953
  0.953
  0.953
  0.953
  0.953
  0.953
  0.953
  0.953
  0.953
Average production assets, $m
  99
  133
  176
  228
  290
  361
  444
  537
  642
  758
  884
  1,021
  1,169
  1,327
  1,496
  1,674
  1,862
  2,059
  2,265
  2,481
  2,707
  2,941
  3,186
  3,440
  3,704
  3,978
  4,263
  4,560
  4,868
  5,188
  5,521
Working capital, $m
  326
  105
  139
  180
  229
  286
  351
  425
  508
  599
  699
  808
  925
  1,050
  1,183
  1,323
  1,472
  1,628
  1,791
  1,962
  2,140
  2,326
  2,519
  2,720
  2,929
  3,146
  3,371
  3,605
  3,849
  4,102
  4,366
Total debt, $m
  140
  222
  323
  445
  590
  759
  954
  1,174
  1,420
  1,692
  1,990
  2,313
  2,661
  3,034
  3,430
  3,850
  4,292
  4,756
  5,243
  5,751
  6,282
  6,835
  7,410
  8,008
  8,630
  9,276
  9,948
  10,646
  11,371
  12,125
  12,910
Total liabilities, $m
  232
  314
  415
  537
  682
  851
  1,046
  1,266
  1,512
  1,784
  2,082
  2,405
  2,753
  3,126
  3,522
  3,942
  4,384
  4,848
  5,335
  5,843
  6,374
  6,927
  7,502
  8,100
  8,722
  9,368
  10,040
  10,738
  11,463
  12,217
  13,002
Total equity, $m
  417
  228
  302
  390
  496
  619
  760
  920
  1,099
  1,297
  1,514
  1,749
  2,002
  2,273
  2,561
  2,866
  3,188
  3,525
  3,879
  4,249
  4,635
  5,037
  5,455
  5,890
  6,342
  6,812
  7,300
  7,807
  8,335
  8,883
  9,454
Total liabilities and equity, $m
  649
  542
  717
  927
  1,178
  1,470
  1,806
  2,186
  2,611
  3,081
  3,596
  4,154
  4,755
  5,399
  6,083
  6,808
  7,572
  8,373
  9,214
  10,092
  11,009
  11,964
  12,957
  13,990
  15,064
  16,180
  17,340
  18,545
  19,798
  21,100
  22,456
Debt-to-equity ratio
  0.336
  0.970
  1.070
  1.140
  1.190
  1.230
  1.250
  1.280
  1.290
  1.300
  1.310
  1.320
  1.330
  1.330
  1.340
  1.340
  1.350
  1.350
  1.350
  1.350
  1.360
  1.360
  1.360
  1.360
  1.360
  1.360
  1.360
  1.360
  1.360
  1.360
  1.370
Adjusted equity ratio
  0.421
  0.421
  0.421
  0.421
  0.421
  0.421
  0.421
  0.421
  0.421
  0.421
  0.421
  0.421
  0.421
  0.421
  0.421
  0.421
  0.421
  0.421
  0.421
  0.421
  0.421
  0.421
  0.421
  0.421
  0.421
  0.421
  0.421
  0.421
  0.421
  0.421
  0.421

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  43
  56
  78
  104
  135
  171
  213
  260
  313
  371
  434
  512
  586
  665
  749
  839
  933
  1,031
  1,135
  1,243
  1,355
  1,473
  1,595
  1,722
  1,854
  1,991
  2,134
  2,282
  2,436
  2,596
  2,763
Depreciation, amort., depletion, $m
  17
  22
  26
  30
  35
  41
  47
  55
  63
  73
  83
  83
  95
  108
  122
  136
  151
  167
  184
  202
  220
  239
  259
  280
  301
  323
  347
  371
  396
  422
  449
Funds from operations, $m
  76
  78
  103
  134
  170
  212
  260
  315
  376
  444
  518
  595
  681
  773
  871
  975
  1,084
  1,199
  1,319
  1,445
  1,576
  1,712
  1,854
  2,002
  2,155
  2,315
  2,481
  2,653
  2,832
  3,018
  3,212
Change in working capital, $m
  3
  27
  34
  41
  49
  57
  65
  74
  83
  91
  100
  109
  117
  125
  133
  141
  148
  156
  163
  171
  178
  186
  193
  201
  209
  217
  225
  234
  244
  253
  263
Cash from operations, $m
  73
  51
  69
  93
  121
  155
  195
  241
  294
  352
  417
  486
  564
  648
  738
  834
  935
  1,043
  1,156
  1,274
  1,397
  1,526
  1,661
  1,801
  1,946
  2,098
  2,255
  2,419
  2,588
  2,765
  2,949
Maintenance CAPEX, $m
  0
  -8
  -11
  -14
  -19
  -24
  -29
  -36
  -44
  -52
  -62
  -72
  -83
  -95
  -108
  -122
  -136
  -151
  -167
  -184
  -202
  -220
  -239
  -259
  -280
  -301
  -323
  -347
  -371
  -396
  -422
New CAPEX, $m
  -3
  -35
  -43
  -52
  -62
  -72
  -83
  -93
  -105
  -116
  -127
  -137
  -148
  -158
  -168
  -178
  -188
  -197
  -207
  -216
  -225
  -235
  -244
  -254
  -264
  -274
  -285
  -296
  -308
  -320
  -333
Cash from investing activities, $m
  -53
  -43
  -54
  -66
  -81
  -96
  -112
  -129
  -149
  -168
  -189
  -209
  -231
  -253
  -276
  -300
  -324
  -348
  -374
  -400
  -427
  -455
  -483
  -513
  -544
  -575
  -608
  -643
  -679
  -716
  -755
Free cash flow, $m
  20
  8
  16
  27
  41
  60
  83
  112
  145
  185
  229
  277
  333
  395
  462
  534
  612
  694
  782
  874
  970
  1,072
  1,177
  1,288
  1,403
  1,522
  1,646
  1,776
  1,910
  2,049
  2,194
Issuance/(repayment) of debt, $m
  140
  82
  101
  122
  145
  169
  194
  220
  246
  272
  298
  323
  348
  373
  396
  419
  442
  465
  487
  509
  531
  553
  575
  598
  622
  646
  672
  698
  725
  754
  785
Issuance/(repurchase) of shares, $m
  -16
  3
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash from financing (excl. dividends), $m  
  118
  85
  101
  122
  145
  169
  194
  220
  246
  272
  298
  323
  348
  373
  396
  419
  442
  465
  487
  509
  531
  553
  575
  598
  622
  646
  672
  698
  725
  754
  785
Total cash flow (excl. dividends), $m
  131
  93
  117
  149
  186
  229
  278
  332
  391
  457
  527
  600
  681
  767
  858
  954
  1,054
  1,159
  1,268
  1,382
  1,501
  1,624
  1,753
  1,886
  2,025
  2,168
  2,318
  2,473
  2,635
  2,803
  2,978
Retained Cash Flow (-), $m
  -26
  -59
  -73
  -89
  -105
  -123
  -141
  -160
  -179
  -198
  -217
  -235
  -253
  -271
  -288
  -305
  -322
  -338
  -354
  -370
  -386
  -402
  -418
  -435
  -452
  -470
  -488
  -507
  -527
  -548
  -571
Prev. year cash balance distribution, $m
 
  248
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
 
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
 
  282
  43
  60
  81
  106
  136
  172
  212
  259
  311
  365
  428
  496
  570
  649
  732
  821
  914
  1,012
  1,115
  1,222
  1,334
  1,451
  1,572
  1,699
  1,830
  1,966
  2,108
  2,255
  2,408
Discount rate, %
 
  4.30
  4.52
  4.74
  4.98
  5.23
  5.49
  5.76
  6.05
  6.35
  6.67
  7.00
  7.35
  7.72
  8.11
  8.51
  8.94
  9.39
  9.86
  10.35
  10.87
  11.41
  11.98
  12.58
  13.21
  13.87
  14.56
  15.29
  16.05
  16.86
  17.70
PV of cash for distribution, $m
 
  270
  40
  52
  66
  82
  99
  116
  133
  149
  163
  173
  183
  189
  191
  190
  186
  179
  168
  156
  142
  126
  111
  95
  80
  66
  53
  42
  33
  25
  18
Current shareholders' claim on cash, %
  100
  99.1
  99.1
  99.1
  99.1
  99.1
  99.1
  99.1
  99.1
  99.1
  99.1
  99.1
  99.1
  99.1
  99.1
  99.1
  99.1
  99.1
  99.1
  99.1
  99.1
  99.1
  99.1
  99.1
  99.1
  99.1
  99.1
  99.1
  99.1
  99.1
  99.1

Natus Medical Incorporated is a provider of newborn care and neurology healthcare products and services used for the screening, diagnosis, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases and balance and mobility disorders. The Company's product offerings include computerized neurodiagnostic systems for audiology, neurology, polysomnography, and neonatology, as well as newborn care products, such as hearing screening systems, phototherapy devices for the treatment of newborn jaundice, head-cooling products for the treatment of brain injury in newborns, incubators to control the newborn's environment, and software systems for managing and tracking disorders and diseases for public health laboratories. The Company is organized into three strategic business units: Neurology, Newborn Care and Otometrics.

FINANCIAL RATIOS  of  Natus Medical (BABY)

Valuation Ratios
P/E Ratio 21.6
Price to Sales 2.4
Price to Book 2.2
Price to Tangible Book
Price to Cash Flow 12.7
Price to Free Cash Flow 13.2
Growth Rates
Sales Growth Rate 1.6%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate -40%
Cap. Spend. - 3 Yr. Gr. Rate -5.6%
Financial Strength
Quick Ratio NaN
Current Ratio 0
LT Debt to Equity 33.6%
Total Debt to Equity 33.6%
Interest Coverage 0
Management Effectiveness
Return On Assets 7.6%
Ret/ On Assets - 3 Yr. Avg. 7.8%
Return On Total Capital 9.1%
Ret/ On T. Cap. - 3 Yr. Avg. 9.5%
Return On Equity 10.6%
Return On Equity - 3 Yr. Avg. 10.2%
Asset Turnover 0.7
Profitability Ratios
Gross Margin 61.5%
Gross Margin - 3 Yr. Avg. 60.8%
EBITDA Margin 18.8%
EBITDA Margin - 3 Yr. Avg. 17.7%
Operating Margin 14.4%
Oper. Margin - 3 Yr. Avg. 13.9%
Pre-Tax Margin 14.4%
Pre-Tax Margin - 3 Yr. Avg. 13.7%
Net Profit Margin 11.3%
Net Profit Margin - 3 Yr. Avg. 10.1%
Effective Tax Rate 21.8%
Eff/ Tax Rate - 3 Yr. Avg. 26.4%
Payout Ratio 0%

BABY stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the BABY stock intrinsic value calculation we used $382 million for the last fiscal year's total revenue generated by Natus Medical. The default revenue input number comes from 2016 income statement of Natus Medical. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our BABY stock valuation model: a) initial revenue growth rate of 35.2% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 4.3%, whose default value for BABY is calculated based on our internal credit rating of Natus Medical, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of Natus Medical.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of BABY stock the variable cost ratio is equal to 83.2%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $9 million in the base year in the intrinsic value calculation for BABY stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 3.5% for Natus Medical.

Corporate tax rate of 27% is the nominal tax rate for Natus Medical. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the BABY stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for BABY are equal to 25.8%.

Life of production assets of 12.3 years is the average useful life of capital assets used in Natus Medical operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for BABY is equal to 20.4%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $417 million for Natus Medical - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 31.414 million for Natus Medical is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of Natus Medical at the current share price and the inputted number of shares is $0.9 billion.

RELATED COMPANIES Price Int.Val. Rating
NURO NeuroMetrix 2.07 0.54  str.sell
CASM CAS Medical Sy 1.07 0.03  str.sell
MASI Masimo 86.61 42.75  sell
GE General Electr 17.35 46.28  str.buy
HOLX Hologic 44.00 6.61  str.sell
BDX Becton Dickins 231.37 68.37  str.sell
PHG Koninklijke Ph 40.02 19.17  sell

COMPANY NEWS

▶ Why Natus Medical Inc Sank Lower Today   [Jan-08-18 12:32PM  Motley Fool]
▶ 4 Growth Stocks to Pick From a Choppy MedTech Market   [Dec-14-17 03:05PM  InvestorPlace]
▶ Stocks With Rising Relative Strength: Natus Medical   [03:00AM  Investor's Business Daily]
▶ Stocks To Watch: Natus Medical Sees Relative Strength Rating Rise To 84   [Nov-08-17 03:00AM  Investor's Business Daily]
▶ Natus Medical Shows Rising Relative Strength; Still Shy Of Key Benchmark   [Oct-31-17 03:00AM  Investor's Business Daily]
▶ Oh Baby! Natus Medical Inc. Beats and Raises Guidance   [Oct-26-17 04:07PM  Motley Fool]
▶ Natus Medical reports 3Q loss   [Oct-25-17 06:23AM  Associated Press]
▶ Natus Medical Inc Looks to Turn Things Around   [Jul-27-17 02:30PM  Motley Fool]
▶ Natus Medical reports 2Q loss   [Jul-26-17 09:54PM  Associated Press]
▶ ETFs with exposure to Natus Medical, Inc. : July 13, 2017   [Jul-13-17 03:34PM  Capital Cube]
▶ ETFs with exposure to Natus Medical, Inc. : June 27, 2017   [Jun-27-17 02:56PM  Capital Cube]
▶ Today's Bell Ringer, June 21, 2107   [Jun-21-17 09:19AM  CNBC Videos]
▶ ETFs with exposure to Natus Medical, Inc. : June 15, 2017   [Jun-15-17 01:12PM  Capital Cube]
▶ Natus to Present at Jefferies 2017 Healthcare Conference   [May-30-17 07:00AM  GlobeNewswire]
▶ Natus Medical to Host Analyst Day on June 22nd   [May-11-17 07:00AM  GlobeNewswire]
▶ Natus Medical Inc. Fell 11% in April. Here's Why.   [May-08-17 03:49PM  Motley Fool]
▶ Why Natus Medical Inc. Sank Today   [Apr-26-17 12:44PM  Motley Fool]
▶ Natus Medical misses 1Q profit forecasts   [08:10AM  Associated Press]
Financial statements of BABY
Follow us on:   twitter   twitter   twitter   twitter

ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2018. All rigths reserved.